Boston Scientific Corp
BSXBuild a strategy around BSX
Boston Scientific Corp AI Insights
Informational only. Not investment advice.Snapshot
- Goodwill of 18.2B is 78% of equity (23.4B) with negative tangible book value (-2.0B) - acquisition-heavy model creates impairment risk.[Goodwill]
- Operating margin TTM 19.2% vs industry median -5.0% - rare profitable player in largely unprofitable medtech peer group.[Operating Margin TTM]
- FCF TTM 3.6B (19% margin) on 5.2% capex intensity funds R&D (10% of revenue) without debt reliance.[Free Cash Flow TTM]
Watch Triggers
- Operating Margin TTM: Falls below 17% — Margin compression signals pricing pressure or integration issues - premium valuation requires margin expansion.
- Goodwill: Impairment charge announced — With negative tangible book, any goodwill impairment directly hits equity and signals overpayment for acquisitions.
- Free Cash Flow TTM: FCF margin drops below 15% — Cash generation funds M&A strategy without dilution - deterioration limits growth optionality.
Bull Case
Dominant profitability in unprofitable industry: 19.2% operating margin vs -5% median creates pricing power moat. 69% gross margin funds 10% R&D spend.
Cash generation machine: 3.6B FCF (78% conversion from operating cash flow) with low capex needs (5%) enables M&A optionality without dilution.
Bear Case
Valuation stretched: P/E 45x vs industry median 32x and P/S 7.3x vs 1.9x median prices in perfection. Any margin miss punishes stock.
Acquisition risk: 18.2B goodwill (78% of equity) from serial M&A. Integration failures or write-downs would devastate negative tangible book.
Bull vs Bear Balance
AI-generated sentiment analysis based on fundamental metrics and market conditions.
Leverage BSX's top insights and create a custom strategy based on them in seconds. Our AI editor does it all — in one click.
Forward Thesis
FCF growth will outpace revenue as R&D leverage improves post-acquisition integration.
- R&D at 10% of revenue vs 12%+ historical
- Operating leverage on 19.3B revenue base
- Debt/equity 0.51 allows continued M&A
Valuation Context
Caveats
BSX Fundamentals
| Metric | Value | YoY Growth | Industry Percentile |
|---|---|---|---|
$72.16B | — | ||
$81.74B | — | ||
20 | — | ||
$20.61B | +17.4% | — | |
$2.39 | +53.4% | — | |
19.9% | +1.4% | — | |
17.3% | +5.7% | — | |
$3.3B | +21.1% | — | |
14.8% | +5.2% | — | |
Beta 5Y (Monthly) | unknown | — |
BSX Dividend History
BSX Stock Splits
BSX SEC Filings
| Filing Date | Report Date | Report Type | Filing Link |
|---|---|---|---|
05/01/26 | 03/31/26 | 10-Q | |
02/17/26 | 12/31/25 | Unknown | |
11/03/25 | 09/30/25 | 10-Q | |
08/01/25 | 06/30/25 | 10-Q | |
05/01/25 | 03/31/25 | 10-Q | |
02/18/25 | 12/31/24 | Unknown | |
11/01/24 | 09/30/24 | 10-Q | |
08/01/24 | 06/30/24 | 10-Q | |
05/01/24 | 03/31/24 | 10-Q | |
02/20/24 | 12/31/23 | 10-K | |
11/01/23 | 09/30/23 | 10-Q | |
08/03/23 | 06/30/23 | 10-Q | |
05/04/23 | 03/31/23 | 10-Q | |
02/23/23 | 12/31/22 | 10-K | |
11/03/22 | 09/30/22 | 10-Q | |
08/04/22 | 06/30/22 | 10-Q | |
05/05/22 | 03/31/22 | 10-Q | |
02/23/22 | 12/31/21 | 10-K | |
11/04/21 | 09/30/21 | 10-Q | |
08/06/21 | 06/30/21 | 10-Q | |
05/06/21 | 03/31/21 | 10-Q | |
02/23/21 | 12/31/20 | 10-K | |
11/05/20 | 09/30/20 | 10-Q | |
08/05/20 | 06/30/20 | 10-Q | |
05/06/20 | 03/31/20 | 10-Q | |
02/25/20 | 12/31/19 | 10-K | |
11/05/19 | 09/30/19 | 10-Q | |
07/30/19 | 06/30/19 | 10-Q | |
04/29/19 | 03/31/19 | 10-Q | |
02/19/19 | 12/31/18 | 10-K | |
10/29/18 | 09/30/18 | 10-Q | |
07/31/18 | 06/30/18 | 10-Q | |
05/01/18 | 03/31/18 | 10-Q | |
02/20/18 | 12/31/17 | 10-K | |
11/02/17 | 09/30/17 | 10-Q | |
08/03/17 | 06/30/17 | 10-Q | |
05/03/17 | 03/31/17 | 10-Q | |
02/23/17 | 12/31/16 | 10-K | |
11/03/16 | 09/30/16 | 10-Q | |
08/03/16 | 06/30/16 | 10-Q | |
05/04/16 | 03/31/16 | 10-Q | |
02/24/16 | 12/31/15 | 10-K | |
11/04/15 | 09/30/15 | 10-Q | |
08/06/15 | 06/30/15 | 10-Q | |
05/06/15 | 03/31/15 | 10-Q | |
02/25/15 | 12/31/14 | 10-K | |
11/05/14 | 09/30/14 | 10-Q | |
08/06/14 | 06/30/14 | 10-Q | |
05/08/14 | 03/31/14 | 10-Q | |
02/26/14 | 12/31/13 | 10-K | |
11/05/13 | 09/30/13 | 10-Q | |
08/07/13 | 06/30/13 | 10-Q | |
05/07/13 | 03/31/13 | 10-Q | |
02/22/13 | 12/31/12 | 10-K | |
11/06/12 | 09/30/12 | 10-Q | |
08/07/12 | 06/30/12 | 10-Q | |
05/03/12 | 03/31/12 | 10-Q | |
02/17/12 | 12/31/11 | 10-K | |
11/08/11 | 09/30/11 | 10-Q | |
08/05/11 | 06/30/11 | 10-Q | |
05/05/11 | 03/31/11 | 10-Q | |
02/17/11 | 12/31/10 | 10-K | |
11/08/11 | 09/30/10 | 10-Q | |
08/05/10 | 06/30/10 | 10-Q | |
05/06/10 | 03/31/10 | 10-Q | |
02/26/10 | 12/31/09 | 10-K | |
11/05/10 | 09/30/09 | 10-Q | |
11/06/09 | 09/30/09 | 10-Q | |
08/06/09 | 06/30/09 | 10-Q | |
05/07/09 | 03/31/09 | 10-Q | |
02/27/09 | 12/31/08 | 10-K | |
11/07/08 | 09/30/08 | 4 | |
08/08/08 | 06/30/08 | 10-Q | |
05/09/08 | 03/31/08 | 10-Q | |
02/28/08 | 12/31/07 | 10-K | |
11/07/07 | 09/30/07 | 10-Q | |
08/08/07 | 06/30/07 | 10-Q | |
05/09/07 | 03/31/07 | 10-Q | |
03/01/07 | 12/31/06 | 10-K | |
11/09/06 | 09/30/06 | 10-Q | |
08/09/06 | 06/30/06 | 8-K | |
05/10/06 | 03/31/06 | 8-K | |
03/01/06 | 12/31/05 | 10-K | |
11/08/05 | 09/30/05 | 10-Q | |
08/09/05 | 06/30/05 | 10-Q | |
05/09/05 | 03/31/05 | 4 | |
03/16/05 | 12/31/04 | 10-K | |
11/09/04 | 09/30/04 | 10-Q | |
08/09/04 | 06/30/04 | 10-Q | |
05/07/04 | 03/31/04 | 10-Q | |
03/15/04 | 12/31/03 | 10-K | |
11/13/03 | 09/30/03 | 4 | |
08/14/03 | 06/30/03 | 10-Q | |
05/15/03 | 03/31/03 | 10-Q | |
03/31/03 | 12/31/02 | 10-K | |
11/14/02 | 09/30/02 | 4 | |
08/09/02 | 06/30/02 | 10-Q | |
05/15/02 | 03/31/02 | 10-Q | |
03/27/02 | 12/31/01 | 10-K | |
11/14/01 | 09/30/01 | 10-Q | |
08/14/01 | 06/30/01 | 10-Q | |
05/15/01 | 03/31/01 | 10-Q | |
04/02/01 | 12/31/00 | 10-K | |
11/13/00 | 09/30/00 | 10-Q | |
08/15/00 | 06/30/00 | 10-Q | |
05/15/00 | 03/31/00 | 10-Q |